Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission
Status:
Completed
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether infliximab can favourably and safely be
discontinued in patients with Crohn's disease in sustained complete clinical, biochemical,
and endoscopic remission on infliximab.
Further to examine the clinical utility of measuring levels/activity of infliximab and
activity of anti-infliximab Ab in patients in sustained complete remission, in order to
investigate whether pharmacoimmunological data can predict the clinical outcome and
rationalize therapeutic management of these patients with respect to continuation or
discontinuation of infliximab therapy. Additional, to investigate the optimal time-point, out
of three, to measure this activity.